TAK-071 Scopolamine-Induced Cognitive Impairment Study

The drug being tested in this study is called TAK-071. This study will look at the effect of
a single oral dose of TAK-071, a novel muscarinic acetylcholine receptor 1 positive
allosteric modulator, on scopolamine-induced deficits in cognitive function in healthy adult
male participants. The study consists of two parts: Part 1 is a substudy to explore PK
profile of TAK-071 in the presence of light meal and coadministration of scopolamine to
determine TAK-071 dose for the next part; Part 2 is the main the study to assess the effects
of TAK-071 on scopolamine-induced cognitive impairment. The study will enroll approximately 6
participants in Part 1 and 40 participants in Part 2. Participant will be assigned to
received TAK-071 along with scopolamine in Part 1 and will be randomly assigned to one of the
ten treatment sequences in Part 2—which will remain undisclosed to the participants and study
doctor during the study (unless there is an urgent medical need):

Part 2: Treatment Sequence ABDEC Part 2: Treatment Sequence BCEAD Part 2: Treatment Sequence
CDABE Part 2: Treatment Sequence DEBCA Part 2: Treatment Sequence EACDB Part 2: Treatment
Sequence ACBED Part 2: Treatment Sequence BDCAE Part 2: Treatment Sequence CEDBA Part 2:
Treatment Sequence DAECB Part 2: Treatment Sequence EBADC Where A=scopolamine matching
placebo SC + TAK-071 matching placebo oral (PO) + donepezil matching placebo PO;
B=scopolamine 0.5 mg SC + TAK-071 matching placebo PO + donepezil matching placebo PO;
C=scopolamine 0.5 mg SC + TAK-071 PO + donepezil matching placebo PO; D=scopolamine 0.5 mg SC
+ TAK-071 PO + donepezil 10 mg PO; and E=scopolamine 0.5 mg SC + TAK-071 matching placebo PO
+ donepezil 10 mg PO.

The dose of TAK-071 that was well-tolerated in the TAK-071-1001 study (NCT02769065) will be
selected, based on the safety and tolerability data from the single-rising dose (SRD) study
for administration in Part 1. Each participant will also receive scopolamine 0.5 mg,
injection, SC, once at the time of Screening. This single center trial will be conducted in
the United States. The overall time to participate in this study is approximately 5.7 weeks
in Part 1 and 21 weeks in Part 2. Participants will remain confined to the clinic for 4 days
during Part 1 and 3 days during the each intervention period in Part 2. Participants will be
contacted by telephone on Day 12 in Part 1 and Day 9 of Period 5 in Part 2 for a follow-up
assessment.

Inclusion Criteria:

1. Weighs at least 50 kilogram (kg) and has a body mass index (BMI) from 18.0 to 30.0
kilogram per square meter (kg/m^2), inclusive at Screening.

Additional inclusion criteria for Part 2:

1. Able to perform the CogState battery.

2. Change from Baseline (average) in total GMLT errors of less than or equal to (<=) -5
at 2 hours postdose of scopolamine.

3. Sleepiness score less than (<) 8 on the karolinska sleepiness scale (KSS) at 2 hours
postdose of scopolamine.

4. Passes a hearing test with at least 80 percent (%) correct responses and no more than
20% false positives. This test can be repeated once to determine eligibility.

Exclusion Criteria:

1. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
abuse (defined as regular consumption of 4 or more units per day) within 1 year prior
to the Screening visit or is unwilling to agree to abstain from alcohol and drugs
throughout the study. One unit is equivalent to a half-pint of beer or 1 measure of
spirits or 1 glass of wine.

2. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to
Check-in Day -1 of Period 1. Cotinine test is positive at Screening or Check-in (Day
-1) of Period 1.

3. Has poor peripheral venous access.

4. Has donated or lost 450 milliliter (mL) or more of his blood volume (including
plasmapheresis), or had a transfusion of any blood product within 30 days prior to Day
1 of Period 1.

5. Is a shift worker (night, late, or early resulting in irregular bed times) or has
crossed or will cross more than 2 time zones within 48 hours in the period from 48
hours prior to Treatment Period 1, Day 1 until the end of Treatment Period 5.

6. Reports symptoms suggesting evidence of a current sleep disorder or history of sleep
disorder, including but not limited to sleep apnea, heavy snoring, primary or chronic
insomnia, narcolepsy or restless leg syndrome, as judged by medical history.